ZeinaAhmadNahlehMD

Oncology • Weston, FL

Chair, Department of Hematology-Oncology Director, Maroon Cancer Center Cleveland Clinic Florida

Join to view full profile

Dr. Nahleh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nahleh's full profile

Already have an account?

Office
2950 Cleveland Clinic Blvd
Weston
Weston, FL 33331
Phone+1 954-659-5840

Fax+1 954-659-5810

Education & Training

George Washington UniversityFellowship, Hematology and Medical Oncology, 1998 - 2003
American University of Beirut Faculty of MedicineClass of 1995

Certifications & Licensure

FL State Medical License 2017 - 2027
TX State Medical License 2011 - 2017
MI State Medical License 2006 - 2014
OH State Medical License 2003 - 2008
DC State Medical License 2002 - 2004
American Board of Internal Medicine Medical Oncology
Association of Clinical Reserach Professionals (ACRP)Certified Principal Investigator (CPI)

Clinical Trials

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer Start of enrollment: 2005 Sep 01
Withdrawn
Phase 2
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Start of enrollment: 2010 Apr 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer Start of enrollment: 2011 Jul 01
Withdrawn
Phase 1, Phase 2
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Neoadjuvant Propanolol in Breast Cancer Start of enrollment: 2015 Sep 01
Terminated
Phase 2
Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer Start of enrollment: 2021 Apr 21
COMPLETED
NA
Roles: Principal Investigator, Contact
Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer Start of enrollment: 2021 Aug 12
WITHDRAWN
NA
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Evaluating survival outcomes and treatment recommendations in resectable gastric cancer.
Saad Sabbagh, Iktej Singh Jabbal, María Herrán, Mohamed Mohanna, Sindu Iska
Scientific Reports. 2025-01-22
2 citations
Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis.
Ali Hijazi, Mohamed Mohanna, Saad Sabbagh, María Herrán, Barbara Dominguez
Breast Cancer Research and Treatment. 2024-08-01
1 citations
Biomarker Testing Disparities in Metastatic Colorectal Cancer.
Saad Sabbagh, María Herrán, Ali Hijazi, Iktej Singh Jabbal, Mohamed Mohanna
JAMA Network Open. 2024-07-01

Lectures

Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database.
2019 ASCO Annual Meeting - 6/1/2019